Compare EJH & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EJH | SBFM |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2019 | 2008 |
| Metric | EJH | SBFM |
|---|---|---|
| Price | $1.34 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 188.7K | ★ 9.9M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,305,891.00 |
| Revenue This Year | N/A | $1.23 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.11 |
| 52 Week Low | $0.08 | $0.21 |
| 52 Week High | $3.07 | $22.00 |
| Indicator | EJH | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 26.29 |
| Support Level | $1.14 | N/A |
| Resistance Level | $1.35 | $1.26 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 16.34 | 2.45 |
E-Home Household Service Holdings Ltd is a household service company providing integrated household services through its website and WeChat platform across China. The company offers services including home appliance and housekeeping services. It operates its business mainly by receiving orders online and providing services offline. Its operations are organized into four reportable segments: appliance installation and maintenance services, housekeeping services, senior care services, and educational consulting services. The company generates the majority of its revenue from installation and maintenance.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.